Steroid hormones are key gene regulators in breast cancer cells. While estrogens stimulate cell proliferation, progestins activate a single cell cycle followed by proliferation arrest. Here, we use biochemical and genome-wide approaches to show that progestins achieve this effect via a functional crosstalk with C/EBPα. Using ChIP-seq, we identify around 1,000 sites where C/EBPα binding precedes and helps binding of progesterone receptor (PR) in response to hormone. These regions exhibit epigenetic marks of active enhancers, and C/EBPα maintains an open chromatin conformation that facilitates loading of ligand-activated PR. Prior to hormone exposure, C/EBPα favors promoter–enhancer contacts that assure hormonal regulation of key genes involv...
Triple-negative breast cancer (TNBC) is characterized by poor response to therapy and low overall pa...
\u3cp\u3eEstrogen receptor α (ERα) is an enhancer activating transcription factor, a key driver of b...
Triple-negative breast cancer (TNBC) is characterized by poor response to therapy and low overall pa...
Steroid hormones are key gene regulators in breast cancer cells. While estrogens stimulate cell prol...
Steroid hormones are key gene regulators in breast cancer cells. While estrogens stimulate cell prol...
Steroid hormones are key gene regulators in breast cancer cells. While estrogens stimulate cell prol...
Trabajo presentado en la IX Jornada de Cromatina i Epigenètica, organizada por la Secció de Cromatin...
Cell cycle regulator p21CIP1 has controversial biological effects in breast cancer since in spite of...
Abstract: Background: Alterations in estrogen and progesterone signaling, via their respective recep...
Progesterone receptor (PR) expression is used as a biomarker of oestrogen receptor-α (ERα) function ...
<p>The progesterone receptor (PR) is a member of the nuclear receptor superfamily of ligand-regulate...
Trabajo presentado en la XI Jornada de Cromatina y Epigenetica, celebrada en modalidad virtual el 14...
Here, we report that in T47D breast cancer cells 50 pM progestin is sufficient to activate cell cycl...
Progesterone receptor (PR) expression is used as a biomarker of oestrogen receptor-α (ERα) function ...
Estrogens are tumor promoters for the mammary gland, due to their ability to control multiple functi...
Triple-negative breast cancer (TNBC) is characterized by poor response to therapy and low overall pa...
\u3cp\u3eEstrogen receptor α (ERα) is an enhancer activating transcription factor, a key driver of b...
Triple-negative breast cancer (TNBC) is characterized by poor response to therapy and low overall pa...
Steroid hormones are key gene regulators in breast cancer cells. While estrogens stimulate cell prol...
Steroid hormones are key gene regulators in breast cancer cells. While estrogens stimulate cell prol...
Steroid hormones are key gene regulators in breast cancer cells. While estrogens stimulate cell prol...
Trabajo presentado en la IX Jornada de Cromatina i Epigenètica, organizada por la Secció de Cromatin...
Cell cycle regulator p21CIP1 has controversial biological effects in breast cancer since in spite of...
Abstract: Background: Alterations in estrogen and progesterone signaling, via their respective recep...
Progesterone receptor (PR) expression is used as a biomarker of oestrogen receptor-α (ERα) function ...
<p>The progesterone receptor (PR) is a member of the nuclear receptor superfamily of ligand-regulate...
Trabajo presentado en la XI Jornada de Cromatina y Epigenetica, celebrada en modalidad virtual el 14...
Here, we report that in T47D breast cancer cells 50 pM progestin is sufficient to activate cell cycl...
Progesterone receptor (PR) expression is used as a biomarker of oestrogen receptor-α (ERα) function ...
Estrogens are tumor promoters for the mammary gland, due to their ability to control multiple functi...
Triple-negative breast cancer (TNBC) is characterized by poor response to therapy and low overall pa...
\u3cp\u3eEstrogen receptor α (ERα) is an enhancer activating transcription factor, a key driver of b...
Triple-negative breast cancer (TNBC) is characterized by poor response to therapy and low overall pa...